Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.35 in the last session, up 6.30% from day before closing price of $1.27. In other words, the price has increased by $6.30 from its previous closing price. On the day, 2.47 million shares were traded.
Ratios:
We take a closer look at ALLO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.71 and its Current Ratio is at 9.71. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.21.
On March 14, 2025, Citizens JMP Upgraded its rating to Mkt Outperform which previously was Mkt Perform but kept the price unchanged to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 21 ’25 when Yoshiyama Annie sold 9,601 shares for $1.41 per share. The transaction valued at 13,537 led to the insider holds 130,663 shares of the business.
Yoshiyama Annie bought 9,601 shares of ALLO for $13,537 on Apr 21 ’25. On Mar 14 ’25, another insider, Chang David D, who serves as the President and CEO of the company, sold 46,668 shares for $1.96 each. As a result, the insider received 91,469 and left with 5,276,569 shares of the company.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is -1.22%, while the 200-Day Moving Average is calculated to be -35.01%.
Shares Statistics:
A total of 218.60M shares are outstanding, with a floating share count of 149.47M. Insiders hold about 31.67% of the company’s shares, while institutions hold 65.89% stake in the company.
Earnings Estimates
The current rating of Allogene Therapeutics Inc (ALLO) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.19 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.74 and -$1.2 for the fiscal current year, implying an average EPS of -$1.0. EPS for the following year is -$0.99, with 10.0 analysts recommending between -$0.55 and -$1.47.
